"ଡାଇହାଇଡ୍ରୋଆର୍ଟେମିସିନିନ/ପିପେରାକୁଇନ" ପୃଷ୍ଠାର ସଂସ୍କରଣଗୁଡ଼ିକ ମଧ୍ୟରେ ତଫାତ
Content deleted Content added
ଟିକେ added Category:ଚିକିତ୍ସା ବିଜ୍ଞାନ using HotCat |
ଅଧିକ ତଥ୍ୟ ଦିଆଗଲା |
||
୪୨ କ ଧାଡ଼ି:
<!-- ସଂଜ୍ଞା ଓ ଲକ୍ଷଣ -->
'''ଡାଇହାଇଡ୍ରୋଆର୍ଟେମିସିନିନ/ପିପେରାକୁଇନ''' ବା '''ଡିଏଚଏ/ପିପିକ୍ୟୁ''' ([[ଇଂରାଜୀ ଭାଷା]]ରେ '''Dihydroartemisinin/piperaquine'''/ '''DHA/PPQ''') ଏକ ସ୍ଥିରୀକୃତ ମାତ୍ରାର ଔଷଧ ମିଶ୍ରଣ ([[:en:fixed dose combination (antiretroviral)|fixed dose combination]]) ଯାହା ଯାହା [[ମ୍ୟାଲେରିଆ]] ରୋଗର ଚିକିତ୍ସାରେ ଦିଆଯାଏ । <ref name=WHO20th/> ଏହି ଔଷଧରେ [[ଡାଇହାଇଡ୍ରୋଆର୍ଟେମିସିନିନ]] ([[:en:dihydroartemisinin|dihydroartemisinin]]) ଓ [[ପିପେରାକୁଇନ]] ([[:en:piperaquine|piperaquine]]) ଔଷଧଦ୍ୱୟ ଥାଏ ।<ref name=WHO20th/> ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ [[ପି ଫାଲସିପାରମ]] (''[[:en:P. falciparum|P. falciparum]]'') ଓ [[ପି ଭାଇଭାକ୍ସ]] (''[[:en:P. vivax|P. vivax]]'') ଧରଣର ମ୍ୟାଲେରିଆ ନିମନ୍ତେ ଦିଆଯାଏ ।<ref name=MMV2017/><ref name=WHO2010/> ଏହା ପାଟିରେ ଦିଆଯାଏ ।<ref name=MMV2017/>
{{^|▼
Side effects are uncommon.<ref name=WHO2010>{{cite web|title=Dihydroartemisinin/Piperaquine Application for Inclusion in the 17th WHO Model List of Essential Medicines|url=http://www.who.int/selection_medicines/committees/expert/18/applications/D_Piperaquine.pdf?ua=1|website=WHO|accessdate=29 June 2017|date=November 2010}}</ref> Concerns include the possibility of [[QT prolongation]].<ref name=WHO2010/> Versions are available for use in children.<ref name=MMV2017/> Use in early [[pregnancy]] is not recommended.<ref name=WHO2010/> The two medications work by different mechanisms.<ref name=WHO2010/>▼
<!-- ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା -->
▲
▲{{^|
<!-- History and culture -->
Dihydroartemisinin/piperaquine was approved for medical use in Europe in 2011.<ref name=MMV2017>{{cite web|title=Eurartesim (dihydroartemisinin-piperaquine) {{!}} Medicines for Malaria Venture|url=https://www.mmv.org/access/products-projects/eurartesim-dihydroartemisinin-piperaquine|website=www.mmv.org|accessdate=13 December 2017|language=en}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO20th>{{cite web|title=WHO Model List of Essential Medicines (20th List)|url=http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1|work=World Health Organization|accessdate=29 June 2017|date=March 2017}}</ref> While it was available for about 6 USD per treatment course, efforts are underway as of 2010 to bring the price down one dollar per course.<ref name=WHO2010/> It is commercially available in Africa and Asia.<ref name=MMV2017/> It has been used to treat more than 4.5 million people as of 2017.<ref name=MMV2017/>
| |||